Biotech Values

[mcbio]

GKTX -

Quote:
Genticel, a biotechnology company developing innovative immunotherapies, and Genkyotex, a Swiss privately-held biopharmaceutical company and the leader in NOX therapies, announced today that Genticel has signed a contribution agreement with the shareholders of Genkyotex pursuant to which…Genkyotex’s shareholders will contribute in kind 100% of the Genkyotex share capital…to Genticel, which will issue new shares in remuneration for the contribution. Upon completion of the proposed transaction, Genkyotex’s shareholders will hold 80% of Genticel’s share capital and voting rights (on a non-diluted basis).

Genkyotex…is developing a portfolio of NADPH oxidase (NOX) oral small molecule inhibitors, which have therapeutic potential for the treatment of multiple significant clinical indications with substantial unmet need.

Genkyotex’s therapeutic approach is based on a selective inhibition of NOX enzymes, which drive a broad range of disease processes, including fibrosis, inflammatory pain, angiogenesis, cancer growth, and neurodegeneration. The seven NOX enzymes form an important new therapeutic target because they modulate multiple signaling pathways implicated in disease by selectively oxidizing key proteins, lipids or DNA.
Good luck with that!

Just to follow up to my post to Peter, I saw this prior post from you on GKTX. Did you make this post due to some specific issue you see in trying to develop an oral small molecule inhibitor against NOX? Is it a concern with the target itself? Concern with being able to hit the target? Or more a concern that this is a completely unproven target and approach?

I found the following interesting: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4543484/ .